This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.


Generic Name
Interferon Gamma
DrugBank Accession Number

Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocytes and natural killer cells.

Biologic Classification
Protein Based Therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Not Available
  • Heberon gamma
  • IFN╬│
  • Recombinant Interferon Gamma
External IDs
  • Interferon Gamma



Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more

Not Available

Mechanism of action

Interferon gamma signals as an antiparallel homodimeric glycoprotein, acting at the complex of interferon gamma receptor 1 (IFNGR1) and IFNGR2 after direct binding to IFNGR1. It activates the JAK/STAT, MAPK, and PI3-Kinase pathways. In addition, Interferon gamma activates macrophages, mediates antiviral and antibacterial immunity, regulates Th1/Th2 balance, and controls cellular proliferation and apoptosis. It is currently being investigated as an antitumor drug, and a therapy for juvenile rheumatoid arthritis, chemoresistant pulmonary tuberculosis, idiopathic pulmonary fibrosis, and atypical pulmonary mycobacteriosis.

This cytokine has been found to have effects such as promotion of host response in antitumor immunity, playing roles in all three phases (elimination, equilibrium, and escape) of cancer immunoediting, directly influencing antiproliferation, apoptosis, and antiangiogenesis on tumor cells, and indirectly influencing antitumor immunity. However, currently there is no approved indication report of using interferon gamma in cancer treatment, indicating that interferon has not yet reached a stage of being a clinically-useful antitumor drug.

Interferon gamma, when administered in combination with interferon alpha-2-beta as part of the HerberFERON therapy, is found to have synergistic effects, with the potential for more favorable pharmacodynamics than either alone. This synergy between interferon alpha and gamma include antiproliferative effects on several cancers.


Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Not Available
Route of elimination

Not Available


Not Available


Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more

Not Available

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Interferon Gamma.
BromotheophyllineThe metabolism of Bromotheophylline can be decreased when combined with Interferon Gamma.
CaffeineThe metabolism of Caffeine can be decreased when combined with Interferon Gamma.
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Interferon Gamma.
MercaptopurineThe metabolism of Mercaptopurine can be decreased when combined with Interferon Gamma.
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Interferon Gamma.
PentoxifyllineThe metabolism of Pentoxifylline can be decreased when combined with Interferon Gamma.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Interferon Gamma.
ZidovudineThe risk or severity of adverse effects can be increased when Interferon Gamma is combined with Zidovudine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available


ATC Codes
L03AB03 — Interferon gamma
Drug Categories
Chemical TaxonomyProvided by Classyfire
Not Available
Organic Compounds
Super Class
Organic Acids
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Alternative Parents
Not Available
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

CAS number
Not Available


General References
  1. de Weerd NA, Nguyen T: The interferons and their receptors--distribution and regulation. Immunol Cell Biol. 2012 May;90(5):483-91. doi: 10.1038/icb.2012.9. Epub 2012 Mar 13. [Article]
  2. McBerry C, Egan CE, Rani R, Yang Y, Wu D, Boespflug N, Boon L, Butcher B, Mirpuri J, Hogan SP, Denkers EY, Aliberti J, Herbert DR: Trefoil factor 2 negatively regulates type 1 immunity against Toxoplasma gondii. J Immunol. 2012 Sep 15;189(6):3078-84. doi: 10.4049/jimmunol.1103374. Epub 2012 Aug 15. [Article]
  3. Bello-Rivero I, Garcia-Vega Y, Duncan-Roberts Y, Vazquez-Blomquistc D, Santana-Milian H, Besada-Perez V, Rios-Cabrera M: HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment. Semin Oncol. 2018 Jan;45(1-2):27-33. doi: 10.1053/j.seminoncol.2018.04.007. Epub 2018 May 4. [Article]
  4. Tau G, Rothman P: Biologic functions of the IFN-gamma receptors. Allergy. 1999 Dec;54(12):1233-51. doi: 10.1034/j.1398-9995.1999.00099.x. [Article]

Clinical Trials

Clinical Trials
4CompletedTreatmentChronic Granulomatous Disease (CGD)1
4TerminatedTreatmentCGD Gene Mutation / CGD Response to IFNg / Chronic Granulomatous Disease (CGD) / IFN-Gamma Therapy / Immunodeficiency Diseases1
3CompletedTreatmentBreast Cancer1
3CompletedTreatmentChronic Prostatitis (CP)1
3CompletedTreatmentExternal Genital Warts / Human Papillomavirus (HPV) Infections1
3CompletedTreatmentGraft Versus Host Disease (cGvHD) / Malignant Lymphomas1
3CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3CompletedTreatmentSepsis / Septic Shock1


Not Available
Not Available
Dosage Forms
Not Available
Not Available
Not Available


Not Available
Experimental Properties
Not Available

Drug created at August 11, 2020 22:11 / Updated at October 07, 2021 12:09